Maresin: Macrophage Mediator for Resolving Inflammation and Bridging Tissue Regeneration—A System-Based Preclinical Systematic Review

Maresins are lipid mediators derived from omega-3 fatty acids with anti-inflammatory and pro-resolving properties, capable of promoting tissue regeneration and potentially serving as a therapeutic agent for chronic inflammatory diseases. The aim of this review was to systematically investigate precl...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 24; no. 13; p. 11012
Main Authors Liu, Wen-Chun, Yang, Yu-Hsin, Wang, Yu-Chin, Chang, Wei-Ming, Wang, Chin-Wei
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.07.2023
MDPI
Subjects
Animals
Anti-Inflammatory Agents
Cardiovascular system
Chronic Disease
Clinical trials
Docosahexaenoic Acids - pharmacology
Docosahexaenoic Acids - therapeutic use
Fatty acids
Health aspects
Humans
Hypotheses
Inflammation
Inflammation - drug therapy
Inflammatory diseases
Kinases
Ligaments
Lipids
Macrophages
Medical research
Medicine, Experimental
Mice
Omega-3 fatty acids
Pain
Pathogens
Peritonitis
Review
Rheumatoid factor
Stem cells
Systematic review
Temporomandibular joint disorders
Tissue engineering
tissue regeneration
maresin
resolving inflammation
preclinical studies
human organ systems
Online AccessGet full text

Cover

Abstract Maresins are lipid mediators derived from omega-3 fatty acids with anti-inflammatory and pro-resolving properties, capable of promoting tissue regeneration and potentially serving as a therapeutic agent for chronic inflammatory diseases. The aim of this review was to systematically investigate preclinical and clinical studies on maresin to inform translational research. Two independent reviewers performed comprehensive searches with the term “Maresin (NOT) Review” on PubMed. A total of 137 studies were included and categorized into 11 human organ systems. Data pertinent to clinical translation were specifically extracted, including delivery methods, optimal dose response, and specific functional efficacy. Maresins generally exhibit efficacy in treating inflammatory diseases, attenuating inflammation, protecting organs, and promoting tissue regeneration, mostly in rodent preclinical models. The nervous system has the highest number of original studies (n = 25), followed by the cardiovascular system, digestive system, and respiratory system, each having the second highest number of studies (n = 18) in the field. Most studies considered systemic delivery with an optimal dose response for mouse animal models ranging from 4 to 25 μg/kg or 2 to 200 ng via intraperitoneal or intravenous injection respectively, whereas human in vitro studies ranged between 1 and 10 nM. Although there has been no human interventional clinical trial yet, the levels of MaR1 in human tissue fluid can potentially serve as biomarkers, including salivary samples for predicting the occurrence of cardiovascular diseases and periodontal diseases; plasma and synovial fluid levels of MaR1 can be associated with treatment response and defining pathotypes of rheumatoid arthritis. Maresins exhibit great potency in resolving disease inflammation and bridging tissue regeneration in preclinical models, and future translational development is warranted.
AbstractList Maresins are lipid mediators derived from omega-3 fatty acids with anti-inflammatory and pro-resolving properties, capable of promoting tissue regeneration and potentially serving as a therapeutic agent for chronic inflammatory diseases. The aim of this review was to systematically investigate preclinical and clinical studies on maresin to inform translational research. Two independent reviewers performed comprehensive searches with the term "Maresin (NOT) Review" on PubMed. A total of 137 studies were included and categorized into 11 human organ systems. Data pertinent to clinical translation were specifically extracted, including delivery methods, optimal dose response, and specific functional efficacy. Maresins generally exhibit efficacy in treating inflammatory diseases, attenuating inflammation, protecting organs, and promoting tissue regeneration, mostly in rodent preclinical models. The nervous system has the highest number of original studies ( = 25), followed by the cardiovascular system, digestive system, and respiratory system, each having the second highest number of studies ( = 18) in the field. Most studies considered systemic delivery with an optimal dose response for mouse animal models ranging from 4 to 25 μg/kg or 2 to 200 ng via intraperitoneal or intravenous injection respectively, whereas human in vitro studies ranged between 1 and 10 nM. Although there has been no human interventional clinical trial yet, the levels of MaR1 in human tissue fluid can potentially serve as biomarkers, including salivary samples for predicting the occurrence of cardiovascular diseases and periodontal diseases; plasma and synovial fluid levels of MaR1 can be associated with treatment response and defining pathotypes of rheumatoid arthritis. Maresins exhibit great potency in resolving disease inflammation and bridging tissue regeneration in preclinical models, and future translational development is warranted.
Maresins are lipid mediators derived from omega-3 fatty acids with anti-inflammatory and pro-resolving properties, capable of promoting tissue regeneration and potentially serving as a therapeutic agent for chronic inflammatory diseases. The aim of this review was to systematically investigate preclinical and clinical studies on maresin to inform translational research. Two independent reviewers performed comprehensive searches with the term "Maresin (NOT) Review" on PubMed. A total of 137 studies were included and categorized into 11 human organ systems. Data pertinent to clinical translation were specifically extracted, including delivery methods, optimal dose response, and specific functional efficacy. Maresins generally exhibit efficacy in treating inflammatory diseases, attenuating inflammation, protecting organs, and promoting tissue regeneration, mostly in rodent preclinical models. The nervous system has the highest number of original studies (n = 25), followed by the cardiovascular system, digestive system, and respiratory system, each having the second highest number of studies (n = 18) in the field. Most studies considered systemic delivery with an optimal dose response for mouse animal models ranging from 4 to 25 μg/kg or 2 to 200 ng via intraperitoneal or intravenous injection respectively, whereas human in vitro studies ranged between 1 and 10 nM. Although there has been no human interventional clinical trial yet, the levels of MaR1 in human tissue fluid can potentially serve as biomarkers, including salivary samples for predicting the occurrence of cardiovascular diseases and periodontal diseases; plasma and synovial fluid levels of MaR1 can be associated with treatment response and defining pathotypes of rheumatoid arthritis. Maresins exhibit great potency in resolving disease inflammation and bridging tissue regeneration in preclinical models, and future translational development is warranted.Maresins are lipid mediators derived from omega-3 fatty acids with anti-inflammatory and pro-resolving properties, capable of promoting tissue regeneration and potentially serving as a therapeutic agent for chronic inflammatory diseases. The aim of this review was to systematically investigate preclinical and clinical studies on maresin to inform translational research. Two independent reviewers performed comprehensive searches with the term "Maresin (NOT) Review" on PubMed. A total of 137 studies were included and categorized into 11 human organ systems. Data pertinent to clinical translation were specifically extracted, including delivery methods, optimal dose response, and specific functional efficacy. Maresins generally exhibit efficacy in treating inflammatory diseases, attenuating inflammation, protecting organs, and promoting tissue regeneration, mostly in rodent preclinical models. The nervous system has the highest number of original studies (n = 25), followed by the cardiovascular system, digestive system, and respiratory system, each having the second highest number of studies (n = 18) in the field. Most studies considered systemic delivery with an optimal dose response for mouse animal models ranging from 4 to 25 μg/kg or 2 to 200 ng via intraperitoneal or intravenous injection respectively, whereas human in vitro studies ranged between 1 and 10 nM. Although there has been no human interventional clinical trial yet, the levels of MaR1 in human tissue fluid can potentially serve as biomarkers, including salivary samples for predicting the occurrence of cardiovascular diseases and periodontal diseases; plasma and synovial fluid levels of MaR1 can be associated with treatment response and defining pathotypes of rheumatoid arthritis. Maresins exhibit great potency in resolving disease inflammation and bridging tissue regeneration in preclinical models, and future translational development is warranted.
Maresins are lipid mediators derived from omega-3 fatty acids with anti-inflammatory and pro-resolving properties, capable of promoting tissue regeneration and potentially serving as a therapeutic agent for chronic inflammatory diseases. The aim of this review was to systematically investigate preclinical and clinical studies on maresin to inform translational research. Two independent reviewers performed comprehensive searches with the term “Maresin (NOT) Review” on PubMed. A total of 137 studies were included and categorized into 11 human organ systems. Data pertinent to clinical translation were specifically extracted, including delivery methods, optimal dose response, and specific functional efficacy. Maresins generally exhibit efficacy in treating inflammatory diseases, attenuating inflammation, protecting organs, and promoting tissue regeneration, mostly in rodent preclinical models. The nervous system has the highest number of original studies (n = 25), followed by the cardiovascular system, digestive system, and respiratory system, each having the second highest number of studies (n = 18) in the field. Most studies considered systemic delivery with an optimal dose response for mouse animal models ranging from 4 to 25 μg/kg or 2 to 200 ng via intraperitoneal or intravenous injection respectively, whereas human in vitro studies ranged between 1 and 10 nM. Although there has been no human interventional clinical trial yet, the levels of MaR1 in human tissue fluid can potentially serve as biomarkers, including salivary samples for predicting the occurrence of cardiovascular diseases and periodontal diseases; plasma and synovial fluid levels of MaR1 can be associated with treatment response and defining pathotypes of rheumatoid arthritis. Maresins exhibit great potency in resolving disease inflammation and bridging tissue regeneration in preclinical models, and future translational development is warranted.
Maresins are lipid mediators derived from omega-3 fatty acids with anti-inflammatory and pro-resolving properties, capable of promoting tissue regeneration and potentially serving as a therapeutic agent for chronic inflammatory diseases. The aim of this review was to systematically investigate preclinical and clinical studies on maresin to inform translational research. Two independent reviewers performed comprehensive searches with the term “Maresin (NOT) Review” on PubMed. A total of 137 studies were included and categorized into 11 human organ systems. Data pertinent to clinical translation were specifically extracted, including delivery methods, optimal dose response, and specific functional efficacy. Maresins generally exhibit efficacy in treating inflammatory diseases, attenuating inflammation, protecting organs, and promoting tissue regeneration, mostly in rodent preclinical models. The nervous system has the highest number of original studies ( n = 25), followed by the cardiovascular system, digestive system, and respiratory system, each having the second highest number of studies ( n = 18) in the field. Most studies considered systemic delivery with an optimal dose response for mouse animal models ranging from 4 to 25 μg/kg or 2 to 200 ng via intraperitoneal or intravenous injection respectively, whereas human in vitro studies ranged between 1 and 10 nM. Although there has been no human interventional clinical trial yet, the levels of MaR1 in human tissue fluid can potentially serve as biomarkers, including salivary samples for predicting the occurrence of cardiovascular diseases and periodontal diseases; plasma and synovial fluid levels of MaR1 can be associated with treatment response and defining pathotypes of rheumatoid arthritis. Maresins exhibit great potency in resolving disease inflammation and bridging tissue regeneration in preclinical models, and future translational development is warranted.
Audience Academic
Author Wang, Yu-Chin
Yang, Yu-Hsin
Chang, Wei-Ming
Wang, Chin-Wei
Liu, Wen-Chun
AuthorAffiliation 3 Division of Periodontics, Department of Dentistry, Taipei Medical University Hospital, Taipei 110301, Taiwan
2 School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei 110301, Taiwan; weiminchang@tmu.edu.tw
1 School of Dentistry, College of Oral Medicine, Taipei Medical University, No. 250, Wuxing St., Taipei 110310, Taiwan; b202108042@tmu.edu.tw (W.-C.L.); b202108010@tmu.edu.tw (Y.-H.Y.); b202107096@tmu.edu.tw (Y.-C.W.)
AuthorAffiliation_xml – name: 2 School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei 110301, Taiwan; weiminchang@tmu.edu.tw
– name: 1 School of Dentistry, College of Oral Medicine, Taipei Medical University, No. 250, Wuxing St., Taipei 110310, Taiwan; b202108042@tmu.edu.tw (W.-C.L.); b202108010@tmu.edu.tw (Y.-H.Y.); b202107096@tmu.edu.tw (Y.-C.W.)
– name: 3 Division of Periodontics, Department of Dentistry, Taipei Medical University Hospital, Taipei 110301, Taiwan
Author_xml – sequence: 1
  givenname: Wen-Chun
  surname: Liu
  fullname: Liu, Wen-Chun
– sequence: 2
  givenname: Yu-Hsin
  surname: Yang
  fullname: Yang, Yu-Hsin
– sequence: 3
  givenname: Yu-Chin
  surname: Wang
  fullname: Wang, Yu-Chin
– sequence: 4
  givenname: Wei-Ming
  orcidid: 0000-0002-6899-4043
  surname: Chang
  fullname: Chang, Wei-Ming
– sequence: 5
  givenname: Chin-Wei
  orcidid: 0000-0001-9679-4121
  surname: Wang
  fullname: Wang, Chin-Wei
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37446190$$D View this record in MEDLINE/PubMed
BookMark eNp1ks1u1DAQxy1URNuFI1cUiQuXFH_FSbigbUWhUlcgKGfL60xSrxx7ayeLeuPWF-AJeRK822XVrUDWyJbn958PzRyjA-cdIPSS4BPGavzWLPpIOWGEYEKfoCPCKc0xFuXBg_chOo5xgTFltKifoUNWci5IjY_Q3UwFiMa9y2ZKB7-8Vh1kM2iMGnzI2mRfIXq7Mq7LLlxrVd-rwXiXKddkp8E03dpzZWIcIaEdOAgb4PfPX9Ps220coM9PVYQm-xJAW-OMVnbrSKBOopWBH8_R01bZCC-29wR9P_9wdfYpv_z88eJseplrXrEhJ5Q2DdYwxzWtK1GVZcOxokQUjeaYl6qYt4pXFcaczIXAHEOhhWp1UfJWCWAT9P4-7nKc99BocENQVi6D6VW4lV4Zue9x5lp2fiUJZpwUqYgJerONEPzNCHGQvYkarFUO_BglrVhFOeWCJvT1I3Thx-BSf2tKcMFwsh3VKQvSuNanxHodVE7LomKkLDdpT_5BpdNAb3Taidak_z3Bq4ed7lr8O_sE5PdAmnuMAdodQrBc75bc263Es0e8NsNm1qkSY_-j-gM-2tOK
CitedBy_id crossref_primary_10_3390_ijms242115528
crossref_primary_10_3390_nano14201642
crossref_primary_10_3390_ijms26052196
crossref_primary_10_1007_s11064_024_04282_x
Cites_doi 10.1016/j.brainres.2022.147936
10.1016/j.jlr.2021.100120
10.5650/jos.ess22183
10.1016/j.hlc.2018.05.102
10.1007/s10571-022-01216-5
10.1111/jcmm.16098
10.1074/jbc.RA117.000885
10.1096/fj.201701493R
10.1016/j.plefa.2017.01.004
10.1038/mi.2015.99
10.1038/s41598-019-39584-6
10.1017/S0007114517002914
10.1016/j.archoralbio.2017.12.023
10.1038/s41569-020-0366-z
10.1186/s12974-022-02386-1
10.1161/CIRCRESAHA.119.315506
10.1177/0022034520917903
10.1038/s41374-018-0031-x
10.1172/JCI124219
10.1038/s42255-022-00590-0
10.1194/jlr.M060392
10.1172/JCI129448
10.1016/j.ebiom.2022.103974
10.3389/fmed.2021.759825
10.1126/scisignal.aan1471
10.1016/j.clnesp.2021.01.013
10.1096/fj.14-259341
10.1194/jlr.RA120000777
10.1371/journal.pone.0102362
10.1038/s41467-020-19176-z
10.1111/jcpe.13173
10.1093/jn/nxac075
10.1152/ajpgi.00078.2019
10.1152/ajpgi.00354.2021
10.1128/mbio.01267-22
10.1002/cphy.c150006
10.1016/j.rdc.2022.03.005
10.1096/fj.202001145R
10.1016/j.ajpath.2019.05.013
10.1096/fj.11-201442
10.12659/MSM.917380
10.1016/j.brainres.2019.01.013
10.1016/j.intimp.2022.109369
10.1002/acr.24596
10.1177/1753425916628618
10.1038/s41467-017-02538-5
10.1073/pnas.2013374118
10.3892/mmr.2017.6711
10.4049/jimmunol.1202743
10.3389/fimmu.2021.691216
10.1155/2016/9203716
10.1016/j.intimp.2022.108912
10.3233/JAD-210559
10.1097/j.pain.0000000000001908
10.2147/JIR.S304811
10.1007/s10753-016-0433-0
10.1097/CCE.0000000000000241
10.3389/fphar.2016.00274
10.1096/fj.201600859R
10.3389/fimmu.2020.585530
10.1371/journal.pone.0070838
10.1523/JNEUROSCI.1395-17.2017
10.1016/j.intimp.2020.107142
10.1096/fj.14-265363
10.1038/s41366-021-01013-y
10.4049/jimmunol.1600837
10.1152/ajpcell.00568.2020
10.1007/s11064-020-03050-x
10.1016/j.trsl.2015.01.001
10.1002/jcp.29846
10.1177/15353702211067465
10.1111/prd.12270
10.1016/j.bioadv.2022.213036
10.1016/j.bcp.2020.114147
10.4049/jimmunol.1502522
10.1096/fj.201900196R
10.1126/sciadv.aax4895
10.1016/j.bcp.2020.114005
10.1016/j.jaci.2019.09.028
10.1155/2021/4131420
10.1016/j.prostaglandins.2021.106576
10.1371/journal.pone.0113480
10.1155/2015/275126
10.2147/JPR.S160779
10.4049/jimmunol.1202969
10.1016/j.amjcard.2021.09.015
10.1096/fj.201900423R
10.1080/03008207.2020.1780218
10.1016/j.freeradbiomed.2019.11.033
10.1096/fj.202100484R
10.1172/JCI96259
10.1084/jem.20081880
10.1186/s13578-021-00734-x
10.1371/journal.pone.0149319
10.1021/acs.biochem.0c00233
10.1096/fj.13-227728
10.1016/j.immuni.2013.10.011
10.1073/pnas.1407123111
10.1155/2020/4539035
10.1111/bph.14647
10.3389/fimmu.2021.674542
10.3389/fphar.2018.00412
10.1093/rap/rkac061
10.1002/jcp.26096
10.1007/s11064-018-2556-1
10.1111/jth.13620
10.3390/ijms23116233
10.1016/j.bja.2018.10.062
10.1186/1465-9921-14-51
10.3390/biomedicines10030674
10.1016/j.molimm.2022.03.118
10.1016/j.lfs.2021.119467
10.1111/jre.12861
10.1016/j.jpain.2021.03.144
10.1038/s42003-022-03169-3
10.1039/D0FO01445A
10.1136/annrheumdis-2018-213511
10.1016/j.neuropharm.2022.109189
10.1111/aji.13206
10.1186/s12950-021-00271-x
10.1038/s41598-020-75353-6
10.1128/IAI.01131-15
10.3390/ijms21020540
10.1007/s11010-018-3392-y
10.1007/s13105-020-00775-9
10.1002/jcp.29628
10.1182/blood-2012-04-423525
10.1097/SHK.0000000000000434
10.2147/DDDT.S188654
10.3390/cells10123406
10.1902/jop.2013.1340019
10.1155/2016/3798465
10.1038/s41598-018-23623-9
10.3389/fphar.2019.01323
10.1186/s12974-022-02405-1
10.1186/s10020-021-00280-9
10.1038/cdd.2017.177
10.1096/fj.201700394R
10.1007/s12035-015-9544-0
10.3389/fphar.2021.782660
10.3390/microorganisms8081156
10.1038/ijo.2017.226
10.1177/00220345221090879
10.1096/fj.202002471R
10.1016/j.prostaglandins.2019.02.007
10.1016/j.prostaglandins.2019.106398
10.1111/pin.13202
10.1111/bph.15906
10.1111/prd.12344
10.1016/j.intimp.2019.105694
10.1016/j.intimp.2019.106018
10.1155/2017/2438247
10.1016/j.bbrc.2016.02.090
10.3389/fncel.2019.00466
10.1136/bmj.n160
10.1096/fj.201600360R
10.1016/j.plefa.2018.04.004
10.1111/acel.13393
10.1016/j.prostaglandins.2018.05.006
10.1016/j.plefa.2019.07.001
10.1002/(SICI)1097-0029(19960301)33:4<296::AID-JEMT2>3.0.CO;2-O
10.1002/mnfr.201900358
10.3389/fnins.2020.00831
10.3233/JAD-201050
10.1016/j.bbi.2017.11.002
10.1111/jcmm.15146
10.1186/s12944-021-01518-5
10.1097/SHK.0000000000000446
10.21203/rs.3.rs-1214060/v1
10.4049/jimmunol.1900236
10.1111/bph.12714
10.1096/fj.201902003R
10.3892/mmr.2016.5639
10.1016/j.bone.2021.116267
10.1161/CIRCRESAHA.116.309492
10.1016/j.bcp.2021.114863
ContentType Journal Article
Copyright COPYRIGHT 2023 MDPI AG
2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023 by the authors. 2023
Copyright_xml – notice: COPYRIGHT 2023 MDPI AG
– notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023 by the authors. 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
M0S
M1P
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
Q9U
7X8
5PM
DOI 10.3390/ijms241311012
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Proquest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
CrossRef
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1422-0067
ExternalDocumentID PMC10341548
A758317748
37446190
10_3390_ijms241311012
Genre Systematic Review
Journal Article
GrantInformation_xml – fundername: Taipei Medical University
  grantid: TMU110-AE1-B27
– fundername: National Science and Technology Council
  grantid: 111-2314-B-038 -162
– fundername: National Science and Technology Council
  grantid: 111-2314-B-038-162
GroupedDBID ---
29J
2WC
53G
5GY
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
8G5
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
AEAQA
AENEX
AFKRA
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
CS3
D1I
DIK
DU5
DWQXO
E3Z
EBD
EBS
EJD
ESX
F5P
FRP
FYUFA
GNUQQ
GUQSH
GX1
HH5
HMCUK
HYE
IAO
IHR
ITC
KQ8
LK8
M1P
M2O
M48
MODMG
O5R
O5S
OK1
OVT
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RPM
TR2
TUS
UKHRP
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7XB
8FK
COVID
K9.
MBDVC
PKEHL
PQEST
PQUKI
Q9U
7X8
5PM
ID FETCH-LOGICAL-c483t-122dd0ceb092986877d40a2165dc4047a5bfa4880041b66040e5c6afc574fa6e3
IEDL.DBID M48
ISSN 1422-0067
1661-6596
IngestDate Thu Aug 21 18:36:52 EDT 2025
Mon Jul 21 11:29:57 EDT 2025
Fri Jul 25 20:19:00 EDT 2025
Tue Jun 17 21:37:56 EDT 2025
Tue Jun 10 21:22:08 EDT 2025
Mon Jul 21 06:04:27 EDT 2025
Tue Jul 01 02:22:20 EDT 2025
Thu Apr 24 23:11:49 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 13
Keywords tissue regeneration
maresin
resolving inflammation
preclinical studies
human organ systems
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c483t-122dd0ceb092986877d40a2165dc4047a5bfa4880041b66040e5c6afc574fa6e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
ORCID 0000-0001-9679-4121
0000-0002-6899-4043
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/ijms241311012
PMID 37446190
PQID 2836463046
PQPubID 2032341
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10341548
proquest_miscellaneous_2838242462
proquest_journals_2836463046
gale_infotracmisc_A758317748
gale_infotracacademiconefile_A758317748
pubmed_primary_37446190
crossref_primary_10_3390_ijms241311012
crossref_citationtrail_10_3390_ijms241311012
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-07-01
PublicationDateYYYYMMDD 2023-07-01
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-01
  day: 01
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle International journal of molecular sciences
PublicationTitleAlternate Int J Mol Sci
PublicationYear 2023
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Fang (ref_104) 2021; 20
Wang (ref_139) 2021; 79
Chiang (ref_40) 2021; 118
Page (ref_11) 2021; 372
Titos (ref_109) 2016; 197
Li (ref_27) 2016; 2016
Fan (ref_90) 2022; 72
Wang (ref_24) 2022; 113
ref_95
Singh (ref_167) 2022; 48
Sugimoto (ref_39) 2022; 4
Olsen (ref_125) 2021; 236
Levy (ref_70) 2020; 145
Do (ref_136) 2023; 43
Wang (ref_142) 2021; 25
Kotlega (ref_143) 2021; 156
Barden (ref_113) 2019; 148
Tojo (ref_184) 2022; 71
Casulleras (ref_103) 2022; 77
ref_126
Ye (ref_107) 2022; 323
Li (ref_18) 2021; 277
Gomez (ref_168) 2020; 11
ref_25
Rao (ref_180) 2019; 203
Souza (ref_177) 2020; 126
Akagi (ref_96) 2015; 29
Wang (ref_64) 2020; 14
Pan (ref_75) 2021; 14
ref_28
Ruiz (ref_43) 2019; 74
Tonetti (ref_81) 2013; 84
Keeley (ref_94) 2022; 162
Lannan (ref_98) 2017; 15
Dalli (ref_3) 2013; 27
Bindu (ref_9) 2020; 180
Du (ref_13) 2018; 87
Wang (ref_44) 2021; 18
Norris (ref_97) 2017; 10
Wang (ref_101) 2016; 8
Laiglesia (ref_38) 2019; 63
See (ref_175) 2017; 118
Laiglesia (ref_29) 2018; 42
Zhuang (ref_72) 2021; 90
Miao (ref_110) 2020; 2020
Korner (ref_120) 2018; 25
Sawada (ref_47) 2018; 8
Werz (ref_119) 2018; 9
Chiang (ref_6) 2019; 129
Tejera (ref_146) 2020; 2
Park (ref_87) 2015; 2015
Han (ref_31) 2019; 129
Qiu (ref_80) 2019; 13
Welty (ref_93) 2021; 35
Qiu (ref_100) 2020; 78
Wang (ref_156) 2015; 44
Gong (ref_152) 2015; 44
Xian (ref_56) 2016; 472
Allen (ref_67) 2020; 161
Xiao (ref_79) 2021; 11
Genco (ref_82) 2020; 83
Sainz (ref_127) 2021; 35
Wahyuni (ref_91) 2021; 321
Chiang (ref_181) 2013; 190
Pistorius (ref_135) 2022; 79
Gao (ref_62) 2018; 11
Markworth (ref_174) 2016; 30
Wang (ref_15) 2020; 99
Jung (ref_30) 2018; 293
Arnardottir (ref_68) 2016; 9
Freedman (ref_5) 2020; 59
Yu (ref_150) 2022; 146
Bartke (ref_108) 1998; 22
Yin (ref_51) 2019; 13
Wake (ref_170) 2021; 42
Caron (ref_133) 2019; 142
Skarke (ref_172) 2015; 56
Regidor (ref_148) 2021; 25
Fattori (ref_61) 2022; 216
Falsetta (ref_69) 2021; 22
Fraenkel (ref_166) 2021; 73
ref_144
Perry (ref_99) 2020; 61
ref_85
Nichols (ref_122) 1996; 33
Fattori (ref_60) 2019; 176
Ou (ref_71) 2021; 2021
Jouvene (ref_116) 2019; 33
Talvani (ref_145) 2020; 83
Li (ref_182) 2013; 39
Costa (ref_48) 2020; 11
Han (ref_73) 2020; 24
Rius (ref_105) 2017; 31
Wu (ref_54) 2022; 108
Munir (ref_35) 2019; 317
Li (ref_77) 2022; 2022
Jung (ref_92) 2018; 448
Wei (ref_65) 2022; 19
English (ref_124) 2017; 117
Norris (ref_183) 2019; 5
Li (ref_21) 2022; 179
Gu (ref_42) 2016; 22
Yang (ref_53) 2019; 122
Zandee (ref_57) 2022; 19
Hopperton (ref_176) 2018; 69
Becker (ref_121) 2019; 189
Nordgren (ref_155) 2013; 14
Serhan (ref_1) 2009; 206
Schlegel (ref_179) 2018; 128
Tang (ref_106) 2021; 27
Jin (ref_50) 2018; 77
Zhang (ref_66) 2018; 9
Dakin (ref_129) 2019; 33
Chen (ref_153) 2016; 39
Li (ref_158) 2021; 12
Mustufvi (ref_84) 2022; 6
Abdulnour (ref_147) 2014; 111
Zhang (ref_102) 2020; 147
Sun (ref_157) 2017; 16
Khedgikar (ref_132) 2022; 155
Colas (ref_140) 2021; 84
Viola (ref_22) 2016; 119
Wu (ref_163) 2021; 8
Chiang (ref_8) 2018; 32
Tavares (ref_149) 2022; 13
Yang (ref_33) 2022; 195
ref_169
Xian (ref_141) 2019; 1711
Laiglesia (ref_128) 2018; 233
Mozurkewich (ref_173) 2016; 7
Lastrucci (ref_118) 2015; 29
Dalli (ref_159) 2012; 120
Leuti (ref_45) 2016; 8
Ohuchi (ref_59) 2018; 43
Hughes (ref_76) 2022; 247
Cezar (ref_46) 2019; 9
Caron (ref_117) 2018; 136
Morita (ref_165) 2021; 62
Li (ref_154) 2020; 235
Lee (ref_162) 2021; 12
Sun (ref_78) 2019; 10
Regan (ref_178) 2022; 152
Marcon (ref_26) 2013; 191
Frangogiannis (ref_88) 2015; 5
Sainz (ref_37) 2021; 77
Yang (ref_17) 2021; 12
Li (ref_55) 2022; 1788
(ref_89) 2018; 27
Li (ref_19) 2016; 2016
Liakh (ref_114) 2022; 46
Gu (ref_20) 2018; 98
Gronert (ref_58) 2017; 37
Laiglesia (ref_36) 2017; 31
Colas (ref_41) 2016; 197
Markworth (ref_130) 2021; 20
Sharma (ref_171) 2020; 60
Rakian (ref_86) 2022; 101
ref_32
Lu (ref_134) 2021; 62
Huang (ref_49) 2020; 34
Lv (ref_34) 2019; 25
Aksoy (ref_161) 2021; 56
Gong (ref_151) 2014; 171
Zhu (ref_137) 2016; 53
Yang (ref_16) 2020; 177
Barden (ref_112) 2018; 133
Nordgren (ref_74) 2015; 166
Yao (ref_131) 2022; 139
Serhan (ref_2) 2012; 26
(ref_160) 2019; 46
Yin (ref_123) 2016; 14
Schulte (ref_115) 2020; 10
Schulte (ref_14) 2020; 11
Genco (ref_83) 2020; 83
Tang (ref_164) 2017; 2017
Shivakoti (ref_111) 2020; 147
Wang (ref_63) 2020; 45
Martinsen (ref_138) 2019; 33
ref_4
Wang (ref_12) 2015; 84
Emre (ref_52) 2022; 5
ref_7
Schjerning (ref_10) 2020; 17
Elder (ref_23) 2021; 35
References_xml – volume: 1788
  start-page: 147936
  year: 2022
  ident: ref_55
  article-title: Maresin 1 improves cognitive decline and ameliorates inflammation and blood-brain barrier damage in rats with chronic cerebral hypoperfusion
  publication-title: Brain Res.
  doi: 10.1016/j.brainres.2022.147936
– volume: 62
  start-page: 100120
  year: 2021
  ident: ref_165
  article-title: Simultaneous analyses of urinary eicosanoids and related mediators identified tetranor-prostaglandin E metabolite as a novel biomarker of diabetic nephropathy
  publication-title: J. Lipid Res.
  doi: 10.1016/j.jlr.2021.100120
– volume: 71
  start-page: 1253
  year: 2022
  ident: ref_184
  article-title: Evaluation of Cancer Cell Growth Suppressibility of ω-3 Fatty Acids and Their Metabolites
  publication-title: J. Oleo Sci.
  doi: 10.5650/jos.ess22183
– volume: 27
  start-page: 1327
  year: 2018
  ident: ref_89
  article-title: Periodontal Disease, Systemic Inflammation and the Risk of Cardiovascular Disease
  publication-title: Heart Lung Circ.
  doi: 10.1016/j.hlc.2018.05.102
– volume: 43
  start-page: 797
  year: 2023
  ident: ref_136
  article-title: Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease
  publication-title: Cell. Mol. Neurobiol.
  doi: 10.1007/s10571-022-01216-5
– volume: 25
  start-page: 434
  year: 2021
  ident: ref_142
  article-title: Maresin 1 attenuates pro-inflammatory activation induced by beta-amyloid and stimulates its uptake
  publication-title: J. Cell. Mol. Med.
  doi: 10.1111/jcmm.16098
– volume: 293
  start-page: 3981
  year: 2018
  ident: ref_30
  article-title: Maresin 1 attenuates NAFLD by suppression of endoplasmic reticulum stress via AMPK-SERCA2b pathway
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA117.000885
– volume: 32
  start-page: 4043
  year: 2018
  ident: ref_8
  article-title: New maresin conjugates in tissue regeneration pathway counters leukotriene D4-stimulated vascular responses
  publication-title: FASEB J.
  doi: 10.1096/fj.201701493R
– volume: 117
  start-page: 17
  year: 2017
  ident: ref_124
  article-title: Identification and Profiling of Specialized Pro-Resolving Mediators in Human Tears by Lipid Mediator Metabolomics
  publication-title: Prostaglandins Leukot. Essent. Fat. Acids
  doi: 10.1016/j.plefa.2017.01.004
– volume: 9
  start-page: 757
  year: 2016
  ident: ref_68
  article-title: Human milk proresolving mediators stimulate resolution of acute inflammation
  publication-title: Mucosal Immunol.
  doi: 10.1038/mi.2015.99
– volume: 9
  start-page: 3062
  year: 2019
  ident: ref_46
  article-title: Treatment with maresin 1, a docosahexaenoic acid-derived pro-resolution lipid, protects skin from inflammation and oxidative stress caused by UVB irradiation
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-019-39584-6
– volume: 118
  start-page: 971
  year: 2017
  ident: ref_175
  article-title: Effects of prenatal n-3 fatty acid supplementation on offspring resolvins at birth and 12 years of age: A double-blind, randomised controlled clinical trial
  publication-title: Br. J. Nutr.
  doi: 10.1017/S0007114517002914
– volume: 87
  start-page: 242
  year: 2018
  ident: ref_13
  article-title: Maresin 1 regulates autophagy and inflammation in human periodontal ligament cells through glycogen synthase kinase-3beta/beta-catenin pathway under inflammatory conditions
  publication-title: Arch. Oral Biol.
  doi: 10.1016/j.archoralbio.2017.12.023
– volume: 17
  start-page: 574
  year: 2020
  ident: ref_10
  article-title: Cardiovascular effects and safety of (non-aspirin) NSAIDs
  publication-title: Nat. Rev. Cardiol.
  doi: 10.1038/s41569-020-0366-z
– volume: 19
  start-page: 27
  year: 2022
  ident: ref_57
  article-title: Administration of Maresin-1 ameliorates the physiopathology of experimental autoimmune encephalomyelitis
  publication-title: J. Neuroinflamm.
  doi: 10.1186/s12974-022-02386-1
– volume: 126
  start-page: 75
  year: 2020
  ident: ref_177
  article-title: Enriched Marine Oil Supplements Increase Peripheral Blood Specialized Pro-Resolving Mediators Concentrations and Reprogram Host Immune Responses: A Randomized Double-Blind Placebo-Controlled Study
  publication-title: Circ. Res.
  doi: 10.1161/CIRCRESAHA.119.315506
– volume: 99
  start-page: 930
  year: 2020
  ident: ref_15
  article-title: Maresin 1 Promotes Wound Healing and Socket Bone Regeneration for Alveolar Ridge Preservation
  publication-title: J. Dent. Res.
  doi: 10.1177/0022034520917903
– volume: 98
  start-page: 715
  year: 2018
  ident: ref_20
  article-title: Maresin 1 attenuates mitochondrial dysfunction through the ALX/cAMP/ROS pathway in the cecal ligation and puncture mouse model and sepsis patients
  publication-title: Lab. Investig.
  doi: 10.1038/s41374-018-0031-x
– volume: 129
  start-page: 1684
  year: 2019
  ident: ref_31
  article-title: A maresin 1/RORalpha/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI124219
– volume: 4
  start-page: 775
  year: 2022
  ident: ref_39
  article-title: Brown adipose tissue-derived MaR2 contributes to cold-induced resolution of inflammation
  publication-title: Nat. Metab.
  doi: 10.1038/s42255-022-00590-0
– volume: 56
  start-page: 1808
  year: 2015
  ident: ref_172
  article-title: Bioactive products formed in humans from fish oils
  publication-title: J. Lipid Res.
  doi: 10.1194/jlr.M060392
– volume: 129
  start-page: 5294
  year: 2019
  ident: ref_6
  article-title: Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI129448
– volume: 79
  start-page: 103974
  year: 2022
  ident: ref_135
  article-title: MCTR3 reprograms arthritic monocytes to upregulate Arginase-1 and exert pro-resolving and tissue-protective functions in experimental arthritis
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2022.103974
– volume: 8
  start-page: 759825
  year: 2021
  ident: ref_163
  article-title: Decreased Serum Maresin 1 Concentration Is Associated With Postmenopausal Osteoporosis: A Cross-Sectional Study
  publication-title: Front. Med.
  doi: 10.3389/fmed.2021.759825
– volume: 10
  start-page: eaan1471
  year: 2017
  ident: ref_97
  article-title: A cluster of immunoresolvents links coagulation to innate host defense in human blood
  publication-title: Sci. Signal.
  doi: 10.1126/scisignal.aan1471
– volume: 42
  start-page: 318
  year: 2021
  ident: ref_170
  article-title: Associations between plasma levels of omega-3 fatty acids and subsequent allergic diseases
  publication-title: Clin. Nutr. ESPEN
  doi: 10.1016/j.clnesp.2021.01.013
– volume: 29
  start-page: 1914
  year: 2015
  ident: ref_118
  article-title: Molecular and cellular profiles of the resolution phase in a damage-associated molecular pattern (DAMP)-mediated peritonitis model and revelation of leukocyte persistence in peritoneal tissues
  publication-title: FASEB J.
  doi: 10.1096/fj.14-259341
– volume: 61
  start-page: 1087
  year: 2020
  ident: ref_99
  article-title: 15-Lipoxygenase-1 biosynthesis of 7S,14S-diHDHA implicates 15-lipoxygenase-2 in biosynthesis of resolvin D5
  publication-title: J. Lipid Res.
  doi: 10.1194/jlr.RA120000777
– ident: ref_4
  doi: 10.1371/journal.pone.0102362
– volume: 11
  start-page: 5420
  year: 2020
  ident: ref_168
  article-title: Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19176-z
– volume: 46
  start-page: 978
  year: 2019
  ident: ref_160
  article-title: Salivary levels of specialized pro-resolving lipid mediators as indicators of periodontal health/disease status
  publication-title: J. Clin. Periodontol.
  doi: 10.1111/jcpe.13173
– volume: 152
  start-page: 1783
  year: 2022
  ident: ref_178
  article-title: Enriched Marine Oil Supplement Increases Specific Plasma Specialized Pro-Resolving Mediators in Adults with Obesity
  publication-title: J. Nutr.
  doi: 10.1093/jn/nxac075
– volume: 317
  start-page: G333
  year: 2019
  ident: ref_35
  article-title: Protective effects of maresin 1 against inflammation in experimentally induced acute pancreatitis and related lung injury
  publication-title: Am. J. Physiol. Gastrointest. Liver Physiol.
  doi: 10.1152/ajpgi.00078.2019
– volume: 323
  start-page: G283
  year: 2022
  ident: ref_107
  article-title: MCTR1 inhibits ferroptosis by promoting NRF2 expression to attenuate hepatic ischemia-reperfusion injury
  publication-title: Am. J. Physiol. Gastrointest. Liver Physiol.
  doi: 10.1152/ajpgi.00354.2021
– volume: 13
  start-page: e0126722
  year: 2022
  ident: ref_149
  article-title: Cysteinyl Maresins Reprogram Macrophages to Protect Mice from Streptococcus pneumoniae after Influenza A Virus Infection
  publication-title: mBio
  doi: 10.1128/mbio.01267-22
– volume: 5
  start-page: 1841
  year: 2015
  ident: ref_88
  article-title: Pathophysiology of Myocardial Infarction
  publication-title: Compr. Physiol.
  doi: 10.1002/cphy.c150006
– volume: 48
  start-page: 679
  year: 2022
  ident: ref_167
  article-title: Treatment Guidelines in Rheumatoid Arthritis
  publication-title: Rheum. Dis. Clin. N. Am.
  doi: 10.1016/j.rdc.2022.03.005
– volume: 34
  start-page: 13521
  year: 2020
  ident: ref_49
  article-title: Maresin 1 resolves aged-associated macrophage inflammation to improve bone regeneration
  publication-title: FASEB J.
  doi: 10.1096/fj.202001145R
– volume: 189
  start-page: 1953
  year: 2019
  ident: ref_121
  article-title: Endogenous Specialized Proresolving Mediator Profiles in a Novel Experimental Model of Lymphatic Obstruction and Intestinal Inflammation in African Green Monkeys
  publication-title: Am. J. Pathol.
  doi: 10.1016/j.ajpath.2019.05.013
– volume: 26
  start-page: 1755
  year: 2012
  ident: ref_2
  article-title: Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain
  publication-title: FASEB J.
  doi: 10.1096/fj.11-201442
– volume: 25
  start-page: 8181
  year: 2019
  ident: ref_34
  article-title: Maresin-1 Inhibits Oxidative Stress and Inflammation and Promotes Apoptosis in a Mouse Model of Caerulein-Induced Acute Pancreatitis
  publication-title: Med. Sci. Monit.
  doi: 10.12659/MSM.917380
– volume: 1711
  start-page: 83
  year: 2019
  ident: ref_141
  article-title: Maresin 1 attenuates the inflammatory response and mitochondrial damage in mice with cerebral ischemia/reperfusion in a SIRT1-dependent manner
  publication-title: Brain Res.
  doi: 10.1016/j.brainres.2019.01.013
– volume: 113
  start-page: 109369
  year: 2022
  ident: ref_24
  article-title: Maresin1 ameliorates ventricular remodelling and arrhythmia in mice models of myocardial infarction via NRF2/HO-1 and TLR4/NF-kB signalling
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2022.109369
– volume: 73
  start-page: 924
  year: 2021
  ident: ref_166
  article-title: 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
  publication-title: Arthritis Care Res.
  doi: 10.1002/acr.24596
– volume: 22
  start-page: 186
  year: 2016
  ident: ref_42
  article-title: Resolvin D1, resolvin D2 and maresin 1 activate the GSK3beta anti-inflammatory axis in TLR4-engaged human monocytes
  publication-title: Innate Immun.
  doi: 10.1177/1753425916628618
– volume: 9
  start-page: 59
  year: 2018
  ident: ref_119
  article-title: Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-017-02538-5
– volume: 118
  start-page: e2013374118
  year: 2021
  ident: ref_40
  article-title: Cysteinyl-specialized proresolving mediators link resolution of infectious inflammation and tissue regeneration via TRAF3 activation
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.2013374118
– volume: 16
  start-page: 1523
  year: 2017
  ident: ref_157
  article-title: Maresin 1 inhibits transforming growth factor-β1-induced proliferation, migration and differentiation in human lung fibroblasts
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2017.6711
– volume: 191
  start-page: 4288
  year: 2013
  ident: ref_26
  article-title: Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1202743
– volume: 12
  start-page: 691216
  year: 2021
  ident: ref_162
  article-title: Subgingival Microbiome and Specialized Pro-Resolving Lipid Mediator Pathway Profiles Are Correlated in Periodontal Inflammation
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.691216
– volume: 2016
  start-page: 9203716
  year: 2016
  ident: ref_27
  article-title: Maresin 1, a Proresolving Lipid Mediator, Mitigates Carbon Tetrachloride-Induced Liver Injury in Mice
  publication-title: Oxid. Med. Cell. Longev.
  doi: 10.1155/2016/9203716
– volume: 108
  start-page: 108912
  year: 2022
  ident: ref_54
  article-title: Maresin 1 alleviates sevoflurane-induced neuroinflammation in neonatal rats via JAK2/STAT3/IL-6 pathways
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2022.108912
– volume: 84
  start-page: 283
  year: 2021
  ident: ref_140
  article-title: Differential Lipid Mediator Involvement in the Different Forms of Genetic Frontotemporal Dementia: Novel Insights into Neuroinflammation
  publication-title: J. Alzheimers Dis.
  doi: 10.3233/JAD-210559
– volume: 161
  start-page: 2155
  year: 2020
  ident: ref_67
  article-title: Imbalance of proresolving lipid mediators in persistent allodynia dissociated from signs of clinical arthritis
  publication-title: Pain
  doi: 10.1097/j.pain.0000000000001908
– volume: 14
  start-page: 1873
  year: 2021
  ident: ref_75
  article-title: MCTR1 Intervention Reverses Experimental Lung Fibrosis in Mice
  publication-title: J. Inflamm. Res.
  doi: 10.2147/JIR.S304811
– volume: 39
  start-page: 1981
  year: 2016
  ident: ref_153
  article-title: Maresin 1 Maintains the Permeability of Lung Epithelial Cells In Vitro and In Vivo
  publication-title: Inflammation
  doi: 10.1007/s10753-016-0433-0
– volume: 2
  start-page: e0241
  year: 2020
  ident: ref_146
  article-title: Plasma Levels of Proresolving and Prophlogistic Lipid Mediators: Association With Severity of Respiratory Failure and Mortality in Acute Respiratory Distress Syndrome
  publication-title: Crit. Care Explor.
  doi: 10.1097/CCE.0000000000000241
– volume: 7
  start-page: 274
  year: 2016
  ident: ref_173
  article-title: Pathway Markers for Pro-resolving Lipid Mediators in Maternal and Umbilical Cord Blood: A Secondary Analysis of the Mothers, Omega-3, and Mental Health Study
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2016.00274
– volume: 31
  start-page: 2135
  year: 2017
  ident: ref_36
  article-title: Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob/ob and diet-induced obese mice
  publication-title: FASEB J.
  doi: 10.1096/fj.201600859R
– volume: 11
  start-page: 585530
  year: 2020
  ident: ref_14
  article-title: Maresin-1 and Resolvin E1 Promote Regenerative Properties of Periodontal Ligament Stem Cells Under Inflammatory Conditions
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.585530
– ident: ref_85
  doi: 10.1371/journal.pone.0070838
– volume: 22
  start-page: 153
  year: 1998
  ident: ref_108
  article-title: The endocrine system: An overview
  publication-title: Alcohol Health Res. World
– volume: 37
  start-page: 11731
  year: 2017
  ident: ref_58
  article-title: Maresin 1 Promotes Inflammatory Resolution, Neuroprotection, and Functional Neurological Recovery After Spinal Cord Injury
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.1395-17.2017
– volume: 90
  start-page: 107142
  year: 2021
  ident: ref_72
  article-title: MCTR3 reduces LPS-induced acute lung injury in mice via the ALX/PINK1 signaling pathway
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2020.107142
– volume: 29
  start-page: 2504
  year: 2015
  ident: ref_96
  article-title: Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice
  publication-title: FASEB J.
  doi: 10.1096/fj.14-265363
– volume: 8
  start-page: 2758
  year: 2016
  ident: ref_101
  article-title: Maresin 1 ameliorates iron-deficient anemia in IL-10(−/−) mice with spontaneous colitis by the inhibition of hepcidin expression though the IL-6/STAT3 pathway
  publication-title: Am. J. Transl. Res.
– volume: 46
  start-page: 408
  year: 2022
  ident: ref_114
  article-title: One-anastomosis gastric bypass modulates the serum levels of pro- and anti-inflammatory oxylipins, which may contribute to the resolution of inflammation
  publication-title: Int. J. Obes.
  doi: 10.1038/s41366-021-01013-y
– volume: 197
  start-page: 4444
  year: 2016
  ident: ref_41
  article-title: Identification and Actions of the Maresin 1 Metabolome in Infectious Inflammation
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1600837
– volume: 321
  start-page: C82
  year: 2021
  ident: ref_91
  article-title: Maresin-1 induces cardiomyocyte hypertrophy through IGF-1 paracrine pathway
  publication-title: Am. J. Physiol. Cell Physiol.
  doi: 10.1152/ajpcell.00568.2020
– volume: 45
  start-page: 1860
  year: 2020
  ident: ref_63
  article-title: A Novel Mechanism of Specialized Proresolving Lipid Mediators Mitigating Radicular Pain: The Negative Interaction with NLRP3 Inflammasome
  publication-title: Neurochem. Res.
  doi: 10.1007/s11064-020-03050-x
– volume: 166
  start-page: 57
  year: 2015
  ident: ref_74
  article-title: Maresin-1 reduces airway inflammation associated with acute and repetitive exposures to organic dust
  publication-title: Transl. Res.
  doi: 10.1016/j.trsl.2015.01.001
– volume: 236
  start-page: 340
  year: 2021
  ident: ref_125
  article-title: Maresin 1, a specialized proresolving mediator, stimulates intracellular [Ca2+] and secretion in conjunctival goblet cells
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.29846
– volume: 77
  start-page: 1303
  year: 2022
  ident: ref_103
  article-title: Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction-associated fatty liver disease
  publication-title: Hepatology
– volume: 247
  start-page: 700
  year: 2022
  ident: ref_76
  article-title: Specialized pro-resolution mediators in the bladder: Receptor expression and recovery of bladder function from cystitis
  publication-title: Exp. Biol. Med.
  doi: 10.1177/15353702211067465
– volume: 83
  start-page: 40
  year: 2020
  ident: ref_83
  article-title: Diabetes as a potential risk for periodontitis: Association studies
  publication-title: Periodontology 2000
  doi: 10.1111/prd.12270
– volume: 139
  start-page: 213036
  year: 2022
  ident: ref_131
  article-title: A cell-free difunctional demineralized bone matrix scaffold enhances the recruitment and osteogenesis of mesenchymal stem cells by promoting inflammation resolution
  publication-title: Biomater. Adv.
  doi: 10.1016/j.bioadv.2022.213036
– volume: 180
  start-page: 114147
  year: 2020
  ident: ref_9
  article-title: Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2020.114147
– volume: 197
  start-page: 3360
  year: 2016
  ident: ref_109
  article-title: Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1502522
– volume: 33
  start-page: 8043
  year: 2019
  ident: ref_129
  article-title: 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture
  publication-title: FASEB J.
  doi: 10.1096/fj.201900196R
– volume: 5
  start-page: eaax4895
  year: 2019
  ident: ref_183
  article-title: Resolution metabolomes activated by hypoxic environment
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.aax4895
– volume: 2022
  start-page: 7177889
  year: 2022
  ident: ref_77
  article-title: Maresin 1 Alleviates Diabetic Kidney Disease via LGR6-Mediated cAMP-SOD2-ROS Pathway
  publication-title: Oxid. Med. Cell. Longev.
– volume: 177
  start-page: 114005
  year: 2020
  ident: ref_16
  article-title: Maresin conjugates in tissue regeneration 1 prevents lipopolysaccharide-induced cardiac dysfunction through improvement of mitochondrial biogenesis and function
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2020.114005
– volume: 145
  start-page: 335
  year: 2020
  ident: ref_70
  article-title: Cysteinyl maresins regulate the prophlogistic lung actions of cysteinyl leukotrienes
  publication-title: J. Allergy Clin. Immunol.
  doi: 10.1016/j.jaci.2019.09.028
– volume: 2021
  start-page: 4131420
  year: 2021
  ident: ref_71
  article-title: The Protective Effects of Maresin 1 in the OVA-Induced Asthma Mouse Model
  publication-title: Mediat. Inflamm.
  doi: 10.1155/2021/4131420
– volume: 156
  start-page: 106576
  year: 2021
  ident: ref_143
  article-title: Prostaglandin E2, 9S-, 13S-HODE and resolvin D1 are strongly associated with the post-stroke cognitive impairment
  publication-title: Prostaglandins Other Lipid Mediat.
  doi: 10.1016/j.prostaglandins.2021.106576
– volume: 25
  start-page: 6782
  year: 2021
  ident: ref_148
  article-title: Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– ident: ref_95
  doi: 10.1371/journal.pone.0113480
– volume: 2015
  start-page: 275126
  year: 2015
  ident: ref_87
  article-title: Maresin 1 Inhibits TRPV1 in Temporomandibular Joint-Related Trigeminal Nociceptive Neurons and TMJ Inflammation-Induced Synaptic Plasticity in the Trigeminal Nucleus
  publication-title: Mediat. Inflamm.
  doi: 10.1155/2015/275126
– volume: 11
  start-page: 1511
  year: 2018
  ident: ref_62
  article-title: Pro-resolving mediator maresin 1 ameliorates pain hypersensitivity in a rat spinal nerve ligation model of neuropathic pain
  publication-title: J. Pain Res.
  doi: 10.2147/JPR.S160779
– volume: 60
  start-page: S112
  year: 2020
  ident: ref_171
  article-title: Use of Specialized Pro-Resolving Mediators to Alleviate Cold Platelet Storage Lesion
  publication-title: Transfusion
– volume: 190
  start-page: 6378
  year: 2013
  ident: ref_181
  article-title: Inhaled carbon monoxide accelerates resolution of inflammation via unique proresolving mediator-heme oxygenase-1 circuits
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1202969
– volume: 162
  start-page: 1
  year: 2022
  ident: ref_94
  article-title: Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women’s Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR] Trial)
  publication-title: Am. J. Cardiol.
  doi: 10.1016/j.amjcard.2021.09.015
– volume: 33
  start-page: 10315
  year: 2019
  ident: ref_138
  article-title: Altered SPMs and age-associated decrease in brain DHA in APOE4 female mice
  publication-title: FASEB J.
  doi: 10.1096/fj.201900423R
– volume: 62
  start-page: 508
  year: 2021
  ident: ref_134
  article-title: Maresin-1 suppresses IL-1β-induced MMP-13 secretion by activating the PI3K/AKT pathway and inhibiting the NF-κB pathway in synovioblasts of an osteoarthritis rat model with treadmill exercise
  publication-title: Connect. Tissue Res.
  doi: 10.1080/03008207.2020.1780218
– volume: 147
  start-page: 23
  year: 2020
  ident: ref_102
  article-title: Maresin 1 mitigates concanavalin A-induced acute liver injury in mice by inhibiting ROS-mediated activation of NF-κB signaling
  publication-title: Free Radic. Biol. Med.
  doi: 10.1016/j.freeradbiomed.2019.11.033
– volume: 35
  start-page: e21780
  year: 2021
  ident: ref_23
  article-title: Maresin 1 activates LGR6 signaling to inhibit smooth muscle cell activation and attenuate murine abdominal aortic aneurysm formation
  publication-title: FASEB J.
  doi: 10.1096/fj.202100484R
– volume: 128
  start-page: 4711
  year: 2018
  ident: ref_179
  article-title: Inhibition of neogenin fosters resolution of inflammation and tissue regeneration
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI96259
– volume: 206
  start-page: 15
  year: 2009
  ident: ref_1
  article-title: Maresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20081880
– volume: 11
  start-page: 221
  year: 2021
  ident: ref_79
  article-title: Maresin conjugates in tissue regeneration-1 suppresses ferroptosis in septic acute kidney injury
  publication-title: Cell Biosci.
  doi: 10.1186/s13578-021-00734-x
– ident: ref_7
  doi: 10.1371/journal.pone.0149319
– volume: 35
  start-page: e21592
  year: 2021
  ident: ref_127
  article-title: Changes in brown adipose tissue lipid mediator signatures with aging, obesity, and DHA supplementation in female mice
  publication-title: FASEB J.
– volume: 59
  start-page: 1832
  year: 2020
  ident: ref_5
  article-title: Biosynthesis of the Maresin Intermediate, 13S,14S-Epoxy-DHA, by Human 15-Lipoxygenase and 12-Lipoxygenase and Its Regulation through Negative Allosteric Modulators
  publication-title: Biochemistry
  doi: 10.1021/acs.biochem.0c00233
– volume: 27
  start-page: 2573
  year: 2013
  ident: ref_3
  article-title: The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype
  publication-title: FASEB J.
  doi: 10.1096/fj.13-227728
– volume: 39
  start-page: 885
  year: 2013
  ident: ref_182
  article-title: Plasticity of leukocytic exudates in resolving acute inflammation is regulated by MicroRNA and proresolving mediators
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.10.011
– volume: 111
  start-page: 16526
  year: 2014
  ident: ref_147
  article-title: Maresin 1 biosynthesis during platelet-neutrophil interactions is organ-protective
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1407123111
– volume: 2020
  start-page: 4539035
  year: 2020
  ident: ref_110
  article-title: Decreased Plasma Maresin 1 Concentration Is Associated with Diabetic Foot Ulcer
  publication-title: Mediat. Inflamm.
  doi: 10.1155/2020/4539035
– volume: 176
  start-page: 1728
  year: 2019
  ident: ref_60
  article-title: The specialised pro-resolving lipid mediator maresin 1 reduces inflammatory pain with a long-lasting analgesic effect
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.14647
– volume: 12
  start-page: 674542
  year: 2021
  ident: ref_17
  article-title: gammadelta T/Interleukin-17A Contributes to the Effect of Maresin Conjugates in Tissue Regeneration 1 on Lipopolysaccharide-Induced Cardiac Injury
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.674542
– volume: 9
  start-page: 412
  year: 2018
  ident: ref_66
  article-title: Distinct Analgesic Actions of DHA and DHA-Derived Specialized Pro-Resolving Mediators on Post-operative Pain After Bone Fracture in Mice
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2018.00412
– volume: 6
  start-page: rkac061
  year: 2022
  ident: ref_84
  article-title: Does periodontal treatment improve rheumatoid arthritis disease activity? A systematic review
  publication-title: Rheumatol. Adv. Pract.
  doi: 10.1093/rap/rkac061
– volume: 233
  start-page: 2238
  year: 2018
  ident: ref_128
  article-title: Maresin 1 inhibits TNF-alpha-induced lipolysis and autophagy in 3T3-L1 adipocytes
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.26096
– volume: 43
  start-page: 1413
  year: 2018
  ident: ref_59
  article-title: A Docosahexaenoic Acid-Derived Pro-resolving Agent, Maresin 1, Protects Motor Neuron Cells Death
  publication-title: Neurochem. Res.
  doi: 10.1007/s11064-018-2556-1
– volume: 15
  start-page: 802
  year: 2017
  ident: ref_98
  article-title: Maresin 1 induces a novel pro-resolving phenotype in human platelets
  publication-title: J. Thromb. Haemost.
  doi: 10.1111/jth.13620
– ident: ref_126
  doi: 10.3390/ijms23116233
– volume: 122
  start-page: 350
  year: 2019
  ident: ref_53
  article-title: Maresin 1 attenuates neuroinflammation in a mouse model of perioperative neurocognitive disorders
  publication-title: Br. J. Anaesth.
  doi: 10.1016/j.bja.2018.10.062
– volume: 14
  start-page: 51
  year: 2013
  ident: ref_155
  article-title: Maresin-1 reduces the pro-inflammatory response of bronchial epithelial cells to organic dust
  publication-title: Respir. Res.
  doi: 10.1186/1465-9921-14-51
– ident: ref_169
  doi: 10.3390/biomedicines10030674
– volume: 146
  start-page: 78
  year: 2022
  ident: ref_150
  article-title: Maresin-2 alleviates allergic airway inflammation in mice by inhibiting the activation of NLRP3 inflammasome, Th2 type immune response and oxidative stress
  publication-title: Mol. Immunol.
  doi: 10.1016/j.molimm.2022.03.118
– volume: 277
  start-page: 119467
  year: 2021
  ident: ref_18
  article-title: Maresin 1 alleviates the inflammatory response, reduces oxidative stress and protects against cardiac injury in LPS-induced mice
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2021.119467
– volume: 56
  start-page: 606
  year: 2021
  ident: ref_161
  article-title: Salivary levels of last generation specific pro-resolving lipid mediators (SPMs) (protectin and maresin) in patients with cardiovascular and periodontal disease: A case-control study
  publication-title: J. Periodontal Res.
  doi: 10.1111/jre.12861
– volume: 22
  start-page: 1195
  year: 2021
  ident: ref_69
  article-title: Specialized Pro-resolving Mediators Reduce Pro-nociceptive Inflammatory Mediator Production in Models of Localized Provoked Vulvodynia
  publication-title: J. Pain
  doi: 10.1016/j.jpain.2021.03.144
– volume: 5
  start-page: 245
  year: 2022
  ident: ref_52
  article-title: Intranasal delivery of pro-resolving lipid mediators rescues memory and gamma oscillation impairment in App(NL-G-F/NL-G-F) mice
  publication-title: Commun. Biol.
  doi: 10.1038/s42003-022-03169-3
– volume: 11
  start-page: 9057
  year: 2020
  ident: ref_48
  article-title: n-3 polyunsaturated fatty acids regulate chemerin in cultured adipocytes: Role of GPR120 and derived lipid mediators
  publication-title: Food Funct.
  doi: 10.1039/D0FO01445A
– volume: 77
  start-page: 1644
  year: 2018
  ident: ref_50
  article-title: Maresin 1 improves the Treg/Th17 imbalance in rheumatoid arthritis through miR-21
  publication-title: Ann. Rheum. Dis.
  doi: 10.1136/annrheumdis-2018-213511
– volume: 216
  start-page: 109189
  year: 2022
  ident: ref_61
  article-title: Maresin 2 is an analgesic specialized pro-resolution lipid mediator in mice by inhibiting neutrophil and monocyte recruitment, nociceptor neuron TRPV1 and TRPA1 activation, and CGRP release
  publication-title: Neuropharmacology
  doi: 10.1016/j.neuropharm.2022.109189
– volume: 83
  start-page: e13206
  year: 2020
  ident: ref_145
  article-title: Pre-eclampsia is associated with reduced resolvin D1 and maresin 1 to leukotriene B4 ratios in the plasma
  publication-title: Am. J. Reprod. Immunol.
  doi: 10.1111/aji.13206
– volume: 18
  start-page: 8
  year: 2021
  ident: ref_44
  article-title: MAR1 suppresses inflammatory response in LPS-induced RAW 264.7 macrophages and human primary peripheral blood mononuclear cells via the SIRT1/PGC-1alpha/PPAR-gamma pathway
  publication-title: J. Inflamm.
  doi: 10.1186/s12950-021-00271-x
– volume: 10
  start-page: 20128
  year: 2020
  ident: ref_115
  article-title: The relationship between specialized pro-resolving lipid mediators, morbid obesity and weight loss after bariatric surgery
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-75353-6
– volume: 84
  start-page: 658
  year: 2015
  ident: ref_12
  article-title: Maresin 1 Biosynthesis and Proresolving Anti-infective Functions with Human-Localized Aggressive Periodontitis Leukocytes
  publication-title: Infect. Immun.
  doi: 10.1128/IAI.01131-15
– ident: ref_32
  doi: 10.3390/ijms21020540
– volume: 448
  start-page: 335
  year: 2018
  ident: ref_92
  article-title: Maresin 1 attenuates pro-inflammatory reactions and ER stress in HUVECs via PPARα-mediated pathway
  publication-title: Mol. Cell. Biochem.
  doi: 10.1007/s11010-018-3392-y
– volume: 77
  start-page: 167
  year: 2021
  ident: ref_37
  article-title: Maresin 1 regulates insulin signaling in human adipocytes as well as in adipose tissue and muscle of lean and obese mice
  publication-title: J. Physiol. Biochem.
  doi: 10.1007/s13105-020-00775-9
– volume: 235
  start-page: 7283
  year: 2020
  ident: ref_154
  article-title: MCTR1 alleviates lipopolysaccharide-induced acute lung injury by protecting lung endothelial glycocalyx
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.29628
– volume: 120
  start-page: e60
  year: 2012
  ident: ref_159
  article-title: Specific lipid mediator signatures of human phagocytes: Microparticles stimulate macrophage efferocytosis and pro-resolving mediators
  publication-title: Blood
  doi: 10.1182/blood-2012-04-423525
– volume: 44
  start-page: 371
  year: 2015
  ident: ref_152
  article-title: Maresin 1 Prevents Lipopolysaccharide-Induced Neutrophil Survival and Accelerates Resolution of Acute Lung Injury
  publication-title: Shock
  doi: 10.1097/SHK.0000000000000434
– volume: 13
  start-page: 739
  year: 2019
  ident: ref_80
  article-title: Maresin 1 mitigates renal ischemia/reperfusion injury in mice via inhibition of the TLR4/MAPK/NF-kappaB pathways and activation of the Nrf2 pathway
  publication-title: Drug Des. Dev. Ther.
  doi: 10.2147/DDDT.S188654
– ident: ref_28
  doi: 10.3390/cells10123406
– volume: 84
  start-page: S24
  year: 2013
  ident: ref_81
  article-title: Periodontitis and atherosclerotic cardiovascular disease: Consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases
  publication-title: J. Periodontol.
  doi: 10.1902/jop.2013.1340019
– volume: 2016
  start-page: 3798465
  year: 2016
  ident: ref_19
  article-title: Maresin 1 Mitigates Inflammatory Response and Protects Mice from Sepsis
  publication-title: Mediat. Inflamm.
  doi: 10.1155/2016/3798465
– volume: 8
  start-page: 5522
  year: 2018
  ident: ref_47
  article-title: Maresin-1 suppresses imiquimod-induced skin inflammation by regulating IL-23 receptor expression
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-018-23623-9
– volume: 10
  start-page: 1323
  year: 2019
  ident: ref_78
  article-title: Maresin 1 Mitigates Sepsis-Associated Acute Kidney Injury in Mice via Inhibition of the NF-kappaB/STAT3/MAPK Pathways
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2019.01323
– volume: 19
  start-page: 32
  year: 2022
  ident: ref_65
  article-title: Maresin 1 promotes nerve regeneration and alleviates neuropathic pain after nerve injury
  publication-title: J. Neuroinflamm.
  doi: 10.1186/s12974-022-02405-1
– volume: 27
  start-page: 18
  year: 2021
  ident: ref_106
  article-title: Maresin 1 protects the liver against ischemia/reperfusion injury via the ALXR/Akt signaling pathway
  publication-title: Mol. Med.
  doi: 10.1186/s10020-021-00280-9
– volume: 25
  start-page: 421
  year: 2018
  ident: ref_120
  article-title: Resolution of inflammation and sepsis survival are improved by dietary Omega-3 fatty acids
  publication-title: Cell Death Differ.
  doi: 10.1038/cdd.2017.177
– volume: 31
  start-page: 5384
  year: 2017
  ident: ref_105
  article-title: The specialized proresolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxia-induced endoplasmic reticulum stress
  publication-title: FASEB J.
  doi: 10.1096/fj.201700394R
– volume: 53
  start-page: 2733
  year: 2016
  ident: ref_137
  article-title: Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Abeta42 Phagocytosis
  publication-title: Mol. Neurobiol.
  doi: 10.1007/s12035-015-9544-0
– volume: 12
  start-page: 782660
  year: 2021
  ident: ref_158
  article-title: Maresin 1 Attenuates Lipopolysaccharide-Induced Acute Kidney Injury via Inhibiting NOX4/ROS/NF-kappaB Pathway
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2021.782660
– ident: ref_25
  doi: 10.3390/microorganisms8081156
– volume: 42
  start-page: 572
  year: 2018
  ident: ref_29
  article-title: Maresin 1 mitigates liver steatosis in ob/ob and diet-induced obese mice
  publication-title: Int. J. Obes.
  doi: 10.1038/ijo.2017.226
– volume: 101
  start-page: 1205
  year: 2022
  ident: ref_86
  article-title: Periodontal Stem Cells Synthesize Maresin Conjugate in Tissue Regeneration 3
  publication-title: J. Dent. Res.
  doi: 10.1177/00220345221090879
– volume: 35
  start-page: e21448
  year: 2021
  ident: ref_93
  article-title: Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B4
  publication-title: FASEB J.
  doi: 10.1096/fj.202002471R
– volume: 142
  start-page: 1
  year: 2019
  ident: ref_133
  article-title: Omega-3 fatty acids and docosahexaenoic acid oxymetabolites modulate the inflammatory response of equine recombinant interleukin1β-stimulated equine synoviocytes
  publication-title: Prostaglandins Other Lipid Mediat.
  doi: 10.1016/j.prostaglandins.2019.02.007
– volume: 147
  start-page: 106398
  year: 2020
  ident: ref_111
  article-title: Lipid mediators of inflammation and Resolution in individuals with tuberculosis and tuberculosis-Diabetes
  publication-title: Prostaglandins Other Lipid Mediat.
  doi: 10.1016/j.prostaglandins.2019.106398
– volume: 72
  start-page: 151
  year: 2022
  ident: ref_90
  article-title: Atherosclerosis: Known and unknown
  publication-title: Pathol. Int.
  doi: 10.1111/pin.13202
– volume: 179
  start-page: 5132
  year: 2022
  ident: ref_21
  article-title: Maresin 1 intervention reverses experimental pulmonary arterial hypertension in mice
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.15906
– volume: 83
  start-page: 7
  year: 2020
  ident: ref_82
  article-title: Clinical and public health implications of periodontal and systemic diseases: An overview
  publication-title: Periodontology 2000
  doi: 10.1111/prd.12344
– volume: 74
  start-page: 105694
  year: 2019
  ident: ref_43
  article-title: Resolvin D1 (RvD1) and maresin 1 (Mar1) contribute to human macrophage control of M. tuberculosis infection while resolving inflammation
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2019.105694
– volume: 8
  start-page: 353ra111
  year: 2016
  ident: ref_45
  article-title: Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses
  publication-title: Sci. Transl. Med.
– volume: 78
  start-page: 106018
  year: 2020
  ident: ref_100
  article-title: Maresin 1 alleviates dextran sulfate sodium-induced ulcerative colitis by regulating NRF2 and TLR4/NF-kB signaling pathway
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2019.106018
– volume: 2017
  start-page: 2438247
  year: 2017
  ident: ref_164
  article-title: Maresin 1 Mitigates High Glucose-Induced Mouse Glomerular Mesangial Cell Injury by Inhibiting Inflammation and Fibrosis
  publication-title: Mediat. Inflamm.
  doi: 10.1155/2017/2438247
– volume: 472
  start-page: 175
  year: 2016
  ident: ref_56
  article-title: The pro-resolving lipid mediator Maresin 1 protects against cerebral ischemia/reperfusion injury by attenuating the pro-inflammatory response
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2016.02.090
– volume: 13
  start-page: 466
  year: 2019
  ident: ref_51
  article-title: Maresin 1 Improves Cognitive Decline and Ameliorates Inflammation in a Mouse Model of Alzheimer’s Disease
  publication-title: Front. Cell. Neurosci.
  doi: 10.3389/fncel.2019.00466
– volume: 372
  start-page: n160
  year: 2021
  ident: ref_11
  article-title: PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews
  publication-title: BMJ
  doi: 10.1136/bmj.n160
– volume: 30
  start-page: 3714
  year: 2016
  ident: ref_174
  article-title: Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid
  publication-title: FASEB J.
  doi: 10.1096/fj.201600360R
– volume: 133
  start-page: 29
  year: 2018
  ident: ref_112
  article-title: The effects of alcohol on plasma lipid mediators of inflammation resolution in patients with Type 2 diabetes mellitus
  publication-title: Prostaglandins Leukot. Essent. Fat. Acids
  doi: 10.1016/j.plefa.2018.04.004
– volume: 20
  start-page: e13393
  year: 2021
  ident: ref_130
  article-title: Metabolipidomic profiling reveals an age-related deficiency of skeletal muscle pro-resolving mediators that contributes to maladaptive tissue remodeling
  publication-title: Aging Cell
  doi: 10.1111/acel.13393
– volume: 136
  start-page: 76
  year: 2018
  ident: ref_117
  article-title: Docosahexaenoic acid-derived oxidized lipid metabolites modulate the inflammatory response of lipolysaccharide-stimulated macrophages
  publication-title: Prostaglandins Other Lipid Mediat.
  doi: 10.1016/j.prostaglandins.2018.05.006
– volume: 148
  start-page: 25
  year: 2019
  ident: ref_113
  article-title: Effect of weight loss on neutrophil resolvins in the metabolic syndrome
  publication-title: Prostaglandins Leukot. Essent. Fat. Acids
  doi: 10.1016/j.plefa.2019.07.001
– volume: 33
  start-page: 296
  year: 1996
  ident: ref_122
  article-title: Conjunctiva
  publication-title: Microsc. Res. Tech.
  doi: 10.1002/(SICI)1097-0029(19960301)33:4<296::AID-JEMT2>3.0.CO;2-O
– volume: 63
  start-page: e1900358
  year: 2019
  ident: ref_38
  article-title: Maresin 1 Regulates Hepatic FGF21 in Diet-Induced Obese Mice and in Cultured Hepatocytes
  publication-title: Mol. Nutr. Food Res.
  doi: 10.1002/mnfr.201900358
– volume: 14
  start-page: 831
  year: 2020
  ident: ref_64
  article-title: Maresin 1 Attenuates Radicular Pain Through the Inhibition of NLRP3 Inflammasome-Induced Pyroptosis via NF-κB Signaling
  publication-title: Front. Neurosci.
  doi: 10.3389/fnins.2020.00831
– volume: 79
  start-page: 607
  year: 2021
  ident: ref_139
  article-title: Reduced Levels of Plasma Lipoxin A4 Are Associated with Post-Stroke Cognitive Impairment
  publication-title: J. Alzheimers Dis.
  doi: 10.3233/JAD-201050
– volume: 69
  start-page: 74
  year: 2018
  ident: ref_176
  article-title: Fish oil feeding attenuates neuroinflammatory gene expression without concomitant changes in brain eicosanoids and docosanoids in a mouse model of Alzheimer’s disease
  publication-title: Brain Behav. Immun.
  doi: 10.1016/j.bbi.2017.11.002
– volume: 24
  start-page: 4736
  year: 2020
  ident: ref_73
  article-title: Maresin Conjugates in Tissue Regeneration 1 improves alveolar fluid clearance by up-regulating alveolar ENaC, Na, K-ATPase in lipopolysaccharide-induced acute lung injury
  publication-title: J. Cell. Mol. Med.
  doi: 10.1111/jcmm.15146
– volume: 20
  start-page: 96
  year: 2021
  ident: ref_104
  article-title: Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: A cross-sectional study
  publication-title: Lipids Health Dis.
  doi: 10.1186/s12944-021-01518-5
– volume: 44
  start-page: 496
  year: 2015
  ident: ref_156
  article-title: Maresin 1 Inhibits Epithelial-to-Mesenchymal Transition in Vitro and Attenuates Bleomycin Induced Lung Fibrosis in Vivo
  publication-title: Shock
  doi: 10.1097/SHK.0000000000000446
– ident: ref_144
  doi: 10.21203/rs.3.rs-1214060/v1
– volume: 203
  start-page: 1031
  year: 2019
  ident: ref_180
  article-title: Vacuolar (H(+))-ATPase Critically Regulates Specialized Proresolving Mediator Pathways in Human M2-like Monocyte-Derived Macrophages and Has a Crucial Role in Resolution of Inflammation
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1900236
– volume: 171
  start-page: 3539
  year: 2014
  ident: ref_151
  article-title: Maresin 1 mitigates LPS-induced acute lung injury in mice
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.12714
– volume: 33
  start-page: 13794
  year: 2019
  ident: ref_116
  article-title: Biosynthetic metabolomes of cysteinyl-containing immunoresolvents
  publication-title: FASEB J.
  doi: 10.1096/fj.201902003R
– volume: 14
  start-page: 3476
  year: 2016
  ident: ref_123
  article-title: Endogenously synthesized n-3 fatty acids in fat-1 transgenic mice prevent melanoma progression by increasing E-cadherin expression and inhibiting β-catenin signaling
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2016.5639
– volume: 155
  start-page: 116267
  year: 2022
  ident: ref_132
  article-title: Mouse LGR6 regulates osteogenesis in vitro and in vivo through differential ligand use
  publication-title: Bone
  doi: 10.1016/j.bone.2021.116267
– volume: 119
  start-page: 1030
  year: 2016
  ident: ref_22
  article-title: Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice
  publication-title: Circ. Res.
  doi: 10.1161/CIRCRESAHA.116.309492
– volume: 195
  start-page: 114863
  year: 2022
  ident: ref_33
  article-title: Maresin 1 protects against lipopolysaccharide/d-galactosamine-induced acute liver injury by inhibiting macrophage pyroptosis and inflammatory response
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2021.114863
SSID ssj0023259
Score 2.4353435
SecondaryResourceType review_article
Snippet Maresins are lipid mediators derived from omega-3 fatty acids with anti-inflammatory and pro-resolving properties, capable of promoting tissue regeneration and...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 11012
SubjectTerms Animals
Anti-Inflammatory Agents
Cardiovascular system
Chronic Disease
Clinical trials
Docosahexaenoic Acids - pharmacology
Docosahexaenoic Acids - therapeutic use
Fatty acids
Health aspects
Humans
Hypotheses
Inflammation
Inflammation - drug therapy
Inflammatory diseases
Kinases
Ligaments
Lipids
Macrophages
Medical research
Medicine, Experimental
Mice
Omega-3 fatty acids
Pain
Pathogens
Peritonitis
Review
Rheumatoid factor
Stem cells
Systematic review
Temporomandibular joint disorders
Tissue engineering
SummonAdditionalLinks – databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagCIlLxT-BgoyE4IJV27EdLxe0RSwFaRGHVuotcuyELirZtrs9cOPGC_CEPAkztjc0SHCMPImszL898w0hz1wZnFTas1Z0mqlJ1zB4tqzkobNOeelCLJD9aPYP1YcjfZQP3Fa5rHJjE6OhDkuPZ-S74AaNMniP9_r0jOHUKLxdzSM0rpJrAjwNlnTZ2bsh4SplHJYmwAcxoycmYWyWkObvLr58XeGVkkB8q5FP-tsyX3JN47LJS35odpNs5wCSThPHb5ErbX-bXE8jJb_dIT_m2FC06F_RucPpXMdgL-g8zuNYnlOIUCke2J_gMQJ933cgD6l3kbo-0D3s3sKVg8gOIP0cUamR4Nf3n1Oa8M3ZHri-QD-Bscx9lXkB0V9pum24Sw5nbw_e7LM8bIF5Zcs1E1KGwH3bcAiYrLFVFRR3UhgdvOKqcrrpHGo7V6IxBnS_1d64zutKdc605T2y1S_79gGh0gpdTTpueID4RGpXBYcvuHZSlRCgFOTl5nfXPiOR40CMkxoyEuROPeJOQZ4P5KcJguNfhC-QdzWqJnzPu9xhALtCkKt6CrkRhEuVsgXZGVGCSvnx8ob7dVbpVf1HAAvydFjGN7FMrW-XF5HGYr-Ngb3cT8IybLmsIPOG8KsgdiRGAwECfY9X-sVxBPwWHGINSC0f_n9fj8gNCUKfiol3yNb6_KJ9DCHTunkS9eI3hgsW1g
  priority: 102
  providerName: ProQuest
Title Maresin: Macrophage Mediator for Resolving Inflammation and Bridging Tissue Regeneration—A System-Based Preclinical Systematic Review
URI https://www.ncbi.nlm.nih.gov/pubmed/37446190
https://www.proquest.com/docview/2836463046
https://www.proquest.com/docview/2838242462
https://pubmed.ncbi.nlm.nih.gov/PMC10341548
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEB7RVkhcEO-almiREFwwrO19BQmhBDUUpFQVaqTcrPWuTYOCQ9NUorfe-gf4hfwSZmzH1LwukaOdtVae2dlvdne-AXhiE29jIV2YR4UMRb_IQvxvwoT7wljhYuurC7IHan8iPkzl9BelUPMBT_8a2lE9qcly_uLbyfkbnPCvKeLEkP3l7POXUzoeioiragO28FlTMYOxaA8UEDdUddNoxyMkD13Tbf7ZvbM8_e6kr6xS3RuUV5ak0S242WBJNqiVfxuu5eUduF5Xlzy_C5djyi2ala_Y2FKhrmN0HWxcleZYLBmCVUZ793PaUWDvywJNo05jZLb0bEiJXNRyVGkGRT9VBNUk8OPi-4DVVOfhEFdBzw7RbzYplk0DEcGy-uDhHkxGe0dv98Om7kLohElWYRTH3nOXZxyxk1FGay-4jSMlvRNcaCuzwtLE5yLKlEI3kEunbOGkFoVVeXIfNstFmW8Di00kdb_ginuEKrG02lvqYPO-ThCrBPB8_blT15CSU22MeYrBCWkn7WgngKet-NeajeNfgs9IdynZDb7P2SbZAEdFfFfpAMMkRE5amAB2O5I4u1y3ea39dG2cKUIyJRSdKQfwuG2mnnRjrcwXZ5WModQbhWN5UBtLO-REYxCOSCwA0zGjVoA4v7st5ey44v6OOMIOjDIf_n_YO3AjRqOv7xXvwuZqeZY_QvS0ynqwoacaf83oXQ-2hnsHhx97tJ7JXjVjfgLXAR2k
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKEYIL4p9AKUbi54JVx7GdLBJCW2DZpd2Kw1bqLTi2QxeVbOluhXrjxgvwHDwUT9KZOFkaJLj1uJpJZO2M5ycz8w0hj03ijJDKMh-XisleWTD4nbGEuzIz0grj6gbZHT3cle_31N4K-dXOwmBbZWsTa0PtZha_kW-AG9RSYx3v1eFXhlujsLrartAIarHlT75ByjZ_OXoD8n0ixODt5PWQNVsFmJVZsmCxEM5x6wsOkUGmszR1khsRa-Ws5DI1qigNqjWXcaE1KLlXVpvSqlSWRvsE3nuBXJQJeHKcTB-8WyZ4iaiXs8Xg85hWPR0wPYGRb0w_f5ljCStGPK2OD_zbE5xxhd02zTN-b3CNXG0CVtoPGnadrPjqBrkUVlie3CQ_xjjANK1e0LHBbWD7YJ_ouN7_MTuiEBFTLBAc4GcLOqpK0L8wK0lN5egmToshZVKLH1g_1SjYyPD7-88-DXjqbBNcraMfwDg3c5wNAdFmaahu3CK75yKG22S1mlX-LqEii1XaK7nmDuIhoUzqDD5gfC9NICCKyPP2785tg3yOCzgOcsiAUDp5RzoRebpkPwyQH_9ifIayy9EUwPusaSYa4FQIqpX3IReD8CyVWUTWOpxwhW2X3Eo_b0zIPP-j8BF5tCTjk9gWV_nZcc2T4XyPhrPcCcqyPHKSQqYP4V5Eso4aLRkQWLxLqab7NcB4zCG2gVT23v_P9ZBcHk7G2_n2aGfrPrki4AKERuY1sro4OvYPIFxbFOv1HaHk43lfylN621Ko
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVCAuiDeGAovE44IVe727tpEQSmijhpIoQq3Um7vetWlQcUqTCvXGjT_Ar-Hn8EuY8YsaCW49RjO2VpnZeXhmvgF4qgOruZDGzfxcuiLOUxd_R27g2TzSwnBtywbZqdreE-_25f4a_GxmYaitsrGJpaG2C0PfyPvoBpVQVMfr53VbxGxz9Ob4i0sbpKjS2qzTqFRkJzv7iunb8vV4E2X9jPPR1u7bbbfeMOAaEQUr1-fcWs9kqYdRQqSiMLTC09xX0hrhiVDLNNek4p7wU6VQ4TNplM6NDEWuVRbgey_BekhZUQ_Wh1vT2Yc23Qt4uarNRw_oKhmrCuEzCGKvP__0eUkFLZ_QtToe8W-_cM4xdps2z3nB0XW4VoevbFDp2w1Yy4qbcLlaaHl2C75PaJxpXrxiE027wQ7RWrFJuQ1kccIwPmZULjiijxhsXOSojdXkJNOFZUOaHSPKbqkMyPqxxMQmhl_ffgxYha7uDtHxWjZDU11PddYEwp5lVa3jNuxdiCDuQK9YFNk9YDzyZRjnnvIsRkdc6tBqekBncRhgeOTAy-bvTkyNg07rOI4SzIdIOklHOg48b9mPKwCQfzG-INklZBjwfUbX8w14KoLYSgaYmWGwForIgY0OJ15o0yU30k9qg7JM_qi_A09aMj1JTXJFtjgteSKa9lF4lruVsrRHDkLM-zH4cyDqqFHLQDDjXUoxPyzhxn0PIx1MbO___1yP4QpeyOT9eLrzAK5y1P-qq3kDequT0-whxm6r9FF9SRgcXPS9_A3jUlg6
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Maresin%3A+Macrophage+Mediator+for+Resolving+Inflammation+and+Bridging+Tissue+Regeneration%E2%80%94A+System-Based+Preclinical+Systematic+Review&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Liu%2C+Wen-Chun&rft.au=Yang%2C+Yu-Hsin&rft.au=Wang%2C+Yu-Chin&rft.au=Chang%2C+Wei-Ming&rft.date=2023-07-01&rft.pub=MDPI+AG&rft.issn=1422-0067&rft.volume=24&rft.issue=13&rft_id=info:doi/10.3390%2Fijms241311012&rft.externalDocID=A758317748
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon